UPDATE 1-Oncolytics lung cancer drug shrinks tumors in 95 pct patients

Fri Feb 8, 2013 2:31pm EST
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article | Single Page
[-] Text [+]

* Says results suggest drug may have potential use in pre-surgical settings

* Shares touch 11-month high of C$4.94 in Toronto (Adds details, analyst comments, shares)

Feb 8 (Reuters) - Oncolytics Biotech Inc said a mid-stage trial of its experimental lung cancer drug showed that 95 percent of the patients experienced a reduction in the size of their tumors, sending its stock up as much as 38 percent.

Shares of the company, with a market value of about C$279 million ($273 million) as of Thursday close, touched an 11-month high of C$4.94, making them among the top percentage gainers on the Toronto Stock Exchange on Friday.

The drug, Reolysin, was used intravenously in combination with chemotherapy drugs carboplatin and paclitaxel. It was tested on patients suffering from metastatic, or recurrent squamous cell carcinoma of the lung.

Squamous cell carcinomas account for about a fourth of all lung cancers, the company said.

However, Oppenheimer & Co analyst Boris Peaker said in a note the single-arm study was inconclusive and the spike in the company's stock price associated with this news was not warranted.

"Since the chemotherapy itself is highly active, it is difficult to estimate the impact that Reolysin is making," said Peaker, who kept his "perform" rating on the stock.

The company said the results further suggest that Reolysin may have potential use in pre-surgical settings.   Continued...